Immunoglobulin A Vasculitis in a Patient on Hemodialysis and With a Metastatic Liver Lesion

Naoki Yamamoto, Akihiro Dejima, Kenkou Hasatani

1. Department of Internal Medicine, Suzu General Hospital, Suzu, JPN

Corresponding author: Naoki Yamamoto, ny0724jp@gmail.com

Abstract

We present the case of a 79-year-old man on hemodialysis with immunoglobulin A (IgA) vasculitis. He developed palpable purpura three weeks after having pneumonia. A skin biopsy showed leukocytoclastic vasculitis with IgA and C3 deposition. He received a topical corticosteroid for his IgA vasculitis. He was also diagnosed with a metastatic liver lesion, which was thought to be of colorectal origin because of the elevations in carcinoembryonic antigen and cancer antigen 19-9 levels. The skin biopsy played an important role in the diagnosis of the patient on hemodialysis. Pneumonia and a metastatic liver lesion thought to be from colorectal cancer might be related to the pathogenesis of IgA vasculitis.

Categories: Dermatology, Allergy/Immunology, Nephrology

Keywords: IgA vasculitis, haemodialysis (HD), henoch-schönlein purpura, metastatic liver lesion

Introduction

Immunoglobulin A (IgA) vasculitis, also known as Henoch-Schönlein purpura (HSP), is a systemic vasculitis characterized by the following tetrad of clinical manifestations: palpable purpura, arthralgia, gastrointestinal symptoms, and renal disease. IgA vasculitis most commonly occurs in children between the ages of four and seven. The incidence rate is estimated to be 14 cases per 100,000 annually [1]. In adults, on the other hand, the annual incidence rate is only 1.3 cases per 100,000, with a mean patient age of 50 years [2]. The American College of Rheumatology diagnostic criteria for HSP include the following: 1) palpable purpura, 2) age of less than 20 years at disease onset, 3) bowel angina, and 4) wall granulocytes on biopsy. HSP can be diagnosed based on the presence of at least two of these criteria with a sensitivity of 87.1% and specificity of 87.7% [3]. In this report, we present a case of IgA vasculitis, which was diagnosed by palpable purpura and a skin biopsy, in a patient on hemodialysis, with recent pneumonia, a metastatic liver lesion, and nephrosclerosis.

Case Presentation

A 79-year-old man with a history of colorectal adenocarcinoma and cholelithiasis was started on hemodialysis a year ago following a CT finding that showed bilateral renal atrophy. He was diagnosed with hypertensive nephrosclerosis at that time; he had been treated with antihypertensives for more than 20 years. He recently presented to the emergency room with epigastralgia, vomiting, and a fever of 39.4 °C. There was no evidence of a rash, arthralgia, or gross hematuria. Laboratory test results were as follows: white blood cell count: 7.8 x 10^6/L; neutrophil count: 7.2 x 10^5/L; hemoglobin level: 11.7 g/dL; platelet count: 16.9 x 10^5/L; total protein: 7.5 mg/dL; albumin: 3.8 g/dL; aspartate aminotransferase: 54 IU/L; alanine aminotransferase: 35 IU/L; alkaline phosphatase: 370 U/L; gamma-glutamyltransferase: 9 IU/L; and C-reactive protein level: 0.40 mg/dL. CT showed bilateral pneumonia and an enlarged hepatic space-occupying lesion (SOL) (Figure 1).
He received sulbactam and cefoperazone for pneumonia and cholangitis. After 10 days, he was discharged from the hospital. Three weeks after the onset of his abdominal symptoms, he noticed a rash on his lower limbs. The rash evolved into palpable purpura after a few days (Figure 2A). Additional laboratory studies showed proteinase-3 antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA almost within the normal limits, at 0.8 IU/mL (normal range: <3.5 IU/mL) and 2.1 IU/mL (normal range: <2.0 IU/mL), respectively. Total protein and albumin were decreased at 6.6 mg/dL and 2.6 g/dL, respectively. Hematoxylin and eosin staining of a skin biopsy showed leukocytoclastic vasculitis (Figure 2B). Immunofluorescence studies showed perivascular deposition of IgA and C3 (Figure 2C).

The patient was diagnosed with IgA vasculitis and received topical corticosteroids, after which the palpable purpura gradually disappeared. A follow-up enhanced CT for cancer showed that the hepatic SOL had a slightly high density in the arterial phase (Figure 3).
Laboratory studies showed that alpha-fetoprotein and protein induced by vitamin K absence or antagonist II were negative, but carcinoembryonic antigen and cancer antigen 19-9 were elevated at 38.6 ng/mL and 519.2 U/mL, respectively. The patient was diagnosed with a metastatic liver lesion most likely of an appendiceal or rectal cancer origin; he did not have hepatitis B, hepatitis C, a habit of drinking alcohol, or non-alcoholic steatohepatitis. He declined to undergo surgery and chemotherapy.

**Discussion**

IgA vasculitis is an IgA antibody-associated small vessel disease. IgA deposition can be observed in the skin, kidneys, and gastrointestinal tract. In one study of 260 adults with IgA vasculitis, all patients were found to have palpable purpura, 61% had a joint disorder, 70% had renal symptoms, and 53% had gastrointestinal symptoms [4].

Our patient presented with palpable purpura that was proven to be a leukocytic vasculitis with IgA and C3 deposition. A typical gastrointestinal symptom is an abdominal pain. In another study, melena and hematemesis were observed in 18 and two patients, respectively, out of 221 patients of less than 16 years in age with IgA vasculitis [5]. Although gastrointestinal vasculitis is not directly confirmed by endoscopy, it is possible that the patient’s epigastralgia and vomiting might have resulted from bowel angina with IgA vasculitis. Palpable purpura typically precedes gastrointestinal symptoms; however, in some cases, it may appear later or not at all [6]. Furthermore, the abdominal symptoms of IgA vasculitis are often overlooked because they are mostly transient and improve without treatment. It may be helpful to measure a serum albumin level to diagnose intestinal involvement in patients without abdominal symptoms [5]. In our case, the patient showed a serum albumin loss from 3.8 to 2.6 g/dL without proteinuria. Renal biopsy was not performed because his bilateral kidneys were atrophic and he was on hemodialysis. There are limited data in the literature/case reports related to IgA vasculitis in patients on hemodialysis [7]. Patients with IgA vasculitis on hemodialysis are less likely to have gross hematuria due to the dysfunction of the glomeruli. Therefore, skin biopsy plays an important role in the diagnosis of these patients.

In the present case, both infection and malignancy could have been triggers for IgA vasculitis. Firstly, the patient had pneumonia before the clinical manifestation of IgA vasculitis. IgA vasculitis is hypothesized to be caused by infections and vaccinations. It is likely that microorganisms have a similar antigenic structure as the blood vessel. Microorganisms could produce cross-reactive antiendothelial cell antibodies, which cause IgA vasculitis. However, specific microorganisms have not yet been detected [8]. Secondly, he had a metastatic lesion of the liver. Paraneoplastic vasculitis accounts for less than 5% of all vasculitis cases [9]. However, 17% of IgA vasculitis patients over 40 years of age had their condition strongly related to malignant tumors [10]. Among IgA vasculitis patients with malignancies, solid tumors accounted for 61% of the malignancies. Patients were mostly over 60 years of age, men, and the most frequent type of solid tumor was lung cancer [11]. Aberrant production of antibodies and tumor antigens, the resemblance of tumor antigens to endothelial cell antigens, and decreased clearance of immune complexes may all potentially play an important role in IgA vasculitis [12]. Screening for malignancies is important in cases of IgA vasculitis in adults, especially in patients on dialysis as they have an increased cancer risk [13].

This was a unique case, and its rarity lies in the fact that a patient with nephrosclerosis on hemodialysis newly developed IgA vasculitis. Infections and malignancies could contribute to the rare combination of IgA vasculitis and hemodialysis. Therefore, we have to investigate whether the patient has underlying infections and malignancies in cases of IgA vasculitis on hemodialysis.
Conclusions
In this report, we described a case of IgA vasculitis in a patient on hemodialysis and with a metastatic liver lesion who had a history of colorectal adenocarcinoma. When a urine analysis or elevated creatinine cannot be used for the diagnosis due to the patient being on hemodialysis, a skin biopsy can be a critical diagnostic tool in patients suspected of having IgA vasculitis, since the prevalence of gastrointestinal symptoms and arthralgia are lower than that of palpable purpura. In patients who are in their fifth decade of life, it is also essential to screen for underlying infections and malignancies, which could cause IgA vasculitis.

Additional Information

Disclosures
Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Rostoker G: Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001, 15:99-138. 10.2165/00063030-200115020-00004
2. Fervenza FC: Henoch-Schönlein purpura nephritis. Int J Dermatol. 2003, 42:170-7. 10.1046/j.1365-4632.2003.01769.x
3. Mills JA, Michel BA, Bloch DA, et al.: The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990, 33:1114-21. 10.1002/art.1780330809
4. Audemard-Verger A, Terrier B, Dechartres A, et al.: Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol. 2017, 69:1862-70. 10.1002/art.40178
5. Jauhola O, Ronkainen J, Koskimies O, et al.: Clinical course of extrarenal symptoms in Henoch-Schönlein purpura: a 6-month prospective study. Arch Dis Child. 2010, 95:871-6. 10.1136/adc.2009.167874
6. Gunasekaran TS, Berman J, Gonzalez M: Duodenaljejunitis: is it idiopathic or is it Henoch-Schönlein purpura without the purpura?. J Pediatr Gastroenterol Nutr. 2000, 30:22-8. 10.1097/00005176-200001000-00013
7. Gao JJ, Wei JM, Gao YH, Li S, Na Y: Central venous catheter infection-induced Henoch-Schönlein purpura in a patient on hemodialysis. Ren Fail. 2014, 36:1145-7. 10.3109/0886022X.2014.917765
8. Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL: The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura. Clin Exp Immunol. 2002, 150:352-7. 10.1046/j.1365-2249.2002.01964.x
9. Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, Selva-O’Callaghan A, Simeón-Aznar CP, Vilardell-Tarres M: Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases . J Rheumatol. 2008, 35:294-304.
10. Mitsui H, Shihagaki N, Kavamura T, Matsue H, Shimada S: A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol. 2009, 23:594-410. 10.1111/j.1468-3083.2008.05065.x
11. Zurada JM, Ward KM, Grossman ME: Henoch-Schönlein purpura associated with malignancy in adults . J Am Acad Dermatol. 2006, 55:565-70. 10.1016/j.jaad.2005.10.011
12. Podjasek HO, Wetter DA, Pfitzner MK, Wada DA: Henoch-Schönlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol. 2012, 92:588-92. 10.2340/00015555-1288
13. Taborelli M, Toffolotti F, Del Zotto S, et al.: Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy. BMC Nephrol. 2019, 20:107. 10.1186/s12882-019-1283-4

2021 Yamamoto et al. Cureus 13(3): e13863. DOI 10.7759/cureus.13863